Will delays in treatment jeopardize the population benefit from extending the time window for stroke thrombolysis?

Stroke

Volumn 43, Issue 11, 2012, Pages 2992-2997

  Pitt, Martin ^a   Monks, Thomas ^a   Agarwal, Paritosh ^b   Worthington, David ^c   Ford, Gary A ^d   Lees, Kennedy R ^e   Stein, Ken ^a   James, Martin A ^f  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b JDA SOFTWARE   (India)

^c LANCASTER UNIVERSITY   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

emergency care; simulation; thrombolysis

Indexed keywords

ALTEPLASE;

ARTICLE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; DISABILITY; DISEASE REGISTRY; HUMAN; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL; THERAPY DELAY; UNITED KINGDOM;

ANTIFIBRINOLYTIC AGENTS; HUMANS; MONTE CARLO METHOD; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84868208762     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.638650     Document Type: Article

References (21)

1. Lees KR, Bluhmki E, Kummer R, Brott T, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS and EPITHET trials. Lancet. 2010;375:1695-1703.
2. Hacke W, Markku K, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945-2948.
4. The European Stroke Organization (ESO) Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack (update 2009). The European Stroke Organization web site. Available at: www.eso-stroke. org/recommendations. php?cid=9&sid=1. Accessed November 30, 2011.
5. Scottish Intercollegiate Guidelines Network. Management of patients with stroke or TIA: Assessment, Investigation, Immediate Management and Secondary Prevention. Available at: www.sign.ac.uk/guidelines/fulltext/108/index.html. Accessed April 13, 2011.
6. Ahmed N, N. W, Grond M, Hennerici MG, Lees KR, Mikulik R, et al. Implementation and outcome of thrombolysis with Alteplase 3-4.5 h after an acute stroke: an update analysis from SITS-ISTR. Lancet Neurol. 2010;9:866-874.
7. Saver JL, Levine SR. Alteplase for ischaemic stroke-much sooner is much better. Lancet. 2010;375:1667-1668.
8. Lyden PC. Thrombolytic therapy for acute stroke-not a moment to lose. N Engl J Med. 2008;359:1393-1395.
9. Chapman KM, Woolfenden AR, Graeb D, Johnston DCC, Beckman J, Schultzer M, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: a Canadian Hospital's experience. Stroke. 2000;31:2920-2924.
10. Romano JG, Muller N, Merino JG, Forteza AM, Koch S, Rabinstein AA. In-hospital delays to stroke thrombolysis: paradoxical effect of early arrival. Neurol Res. 2007;29:664-666.
11. Heo JH, Kim YD, Nam HS, Hong KS, Ahn SH, Cho HJ, et al. A computerised in-hospital alert system for thrombolysis in acute stroke. Stroke. 2010;41:1978-1983.
12. Ferrari J, Knoflach M, Kiechl S, Willeit J, Matosevic B, Seyfang L, et al. Stroke thrombolysis: having more time translates into delayed therapy: data from the Austrian Stroke Unit Registry. Stroke. 2010;41:2001-2004.
13. Saver JL, Smith EE, Fonarow GC, Reeves MJ, Xin Z, Olson DM, et al. on behalf of the GWTG-Stroke Steering Committee and Investigators. The 'golden hour' and acute brain ischemia; presenting features and lytic therapy in 30 000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41:1431-1439.
14. Lees KR, Ford GA, Muir KW, Ahmed N, Dyker AG, Atula S, et al. Thrombolytic therapy for acute stroke in the United Kingdom: experience from the Safe Implementation of Thrombolysis in Stroke (SITS) register. QJM. 2008;101:863-869.
15. The NINDS Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
16. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282.
17. Bembenek J, Kobayashi A, Sandercock P, Czlonkowska A. How many patients might receive thrombolytic therapy in the light of the ECASS-3 and IST-3 data? Int J Stroke. 2010;5:430.
18. Cooksey D. A Review of UK Health Research Funding. London, UK: HM Stationery Office; 2006.
19. Asplund K, Glader E-L, Norrving B, Eriksson M; for the Riks-Stroke Collaboration. Effects of extending the time window of thrombolysis to 4.5 hours. Observations in the Swedish Stroke Register (RIKS-Stroke). Stroke. 2011;42:2492-2497.
20. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke. Stroke. 2007;38:1655-1671.
21. Intercollegiate Stroke Working Party. National Sentinel Stroke Audit 2010 Round 7. London, UK: Royal College of Physicians of London; 2011.